TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01362517

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quinvaxem
Description: A single dose (0.5 mL) of Quinvaxem contains:~diphtheria antitoxin (\>= 30 IU), tetanus antitoxin (\>= 60 IU), whole-cell inactive pertussis bacteria (\>= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen~One dose of Quinvaxem given at 2, 3 and 4 months of age
Study: NCT04475237

Intervention type: OTHER
Intervention: CT-scan evaluation and segmentation
Description: CT-scans will be evaluated (to see if they are included in the research group) and segmented if they are accepted.
Study: NCT00507832

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pimecrolimus
Description: twice daily topical

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: twice daily topical

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pimecrolimus
Description: topical application as a cream twice daily
Study: NCT01487213

Intervention type: OTHER
Group type: OTHER
Intervention: Home self assessment of complete medical abortion
Description: Self assessment of complete abortion using a home semiquantitative U-hCG test. Follow-up out patient review two-three weeks later by qualified practitioner to evaluate success of procedure using the clinic's standard routine. The patient charts will be reviewed after three months in order to control for possible extra visits related to abortion-related complications.
Study: NCT00310076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Patients will receive thalidomide orally each evening for 24 months or until tumor progression is detected.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: Cytoreductive Surgery with Intraperitoneal Hyperthermic Chemotherapy
Study: NCT01575041

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sodium
Description: Sodium Chloride (provided by Microz, Geleen, Netherlands): 8 capsules per day which equals a sodium intake of 3 grams.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium
Description: Sodium Chloride (provided by Microz, Geleen, Netherlands): 8 capsules per day which equals a sodium intake of 3 grams.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium
Description: Sodium Chloride (provided by Microz, Geleen, Netherlands): 8 capsules per day which equals a sodium intake of 3 grams.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium
Description: Potassium Chloride (provided by Microz, Geleen, Netherlands): 8 capsules per day which equals a potassium intake of 3 grams.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (cellulose, provided by Microz, Geleen, Netherlands): 8 capsules per day.
Study: NCT04310475

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality assisted CBT
Description: This study uses virtual reality technology to assist cognitive behavioural therapy for social difficulties in people with first episode psychosis.
Study: NCT01724801

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: whole brain radiation(WBI)
Description: WBI (30Gy/3Gy/10 fractions) plus concurrent or sequential chemotherapy for 4-6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: administered orally at a dose of 125 mg 3 times daily
Study: NCT02628509

Intervention type: DEVICE
Intervention: cardiac devices
Description: patients receiving mechanical circulatory support or undergoing trans aortic valve replacement
Study: NCT02224183

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Individuals randomized to the education group will receive The Back Pain Helpbook, an educational book with strategies for self-care including an exercise program, lifestyle modification, and tips for managing flare-ups. In addition, they will receive an assignment sheet outlining specific chapters to read over the course of the 12-weeks. In addition, participants receive at 3, 6, 9, and 12 weeks newsletters highlighting main points from the assigned chapters.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: Weekly yoga classes will each be taught by two yoga instructors. Classes will be 75 minutes long. Mats and props will be provided. Yoga participants will be encouraged to practice for 30 minutes on days when they do not have class. They will be provided free of charge with a participant handbook, mat, block, and strap to aid home practice. Yoga home practice videos will be placed online for home practice and the website will track time spent using the videos for home practice. DVDs will be provided for those that do not have consistent access to the internet at home.
Study: NCT00935714

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Study: NCT04474613

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Liquid biopsy
Description: Liquid biopsy done on a blood draw, taking approximately 7 days
Study: NCT00053508

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACAM1000
Description: Group 1 dose: 1.4 x 10-8th PFU/ml (350,000 PFU) Group 2 dose: 2.8 x 10-7th PFU/ml (70,000 PFU) Group 3 dose: 5.6 x 10-6th PFU/ml (14,000 PFU)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACAM1000
Description: Group 1 dose: 1.4 x 10-8th PFU/ml (350,000 PFU) Group 2 dose: 2.8 x 10-7th PFU/ml (70,000 PFU) Group 3 dose: 5.6 x 10-6th PFU/ml (14,000 PFU)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACAM1000
Description: Group 1 dose: 1.4 x 10-8th PFU/ml (350,000 PFU) Group 2 dose: 2.8 x 10-7th PFU/ml (70,000 PFU) Group 3 dose: 5.6 x 10-6th PFU/ml (14,000 PFU)
Study: NCT00053508

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: vaccinia virus (calf lymph) smallpox vaccine: Dryvax
Description: group 4 dose: 1.6 x 10-8th PFU/ml (250,000 PFU)
Study: NCT01290198

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Microdialysis of fluconazole, vehicle and N(G)-nitro-L-arginine-methyl ester (L-NMMA)
Description: At the first three visits, volunteers will receive fluconazole (650µmol/L and 6.5mmol/L) and vehicle (NaCl 0.9%), and at the fourth, these plus L-NMMA (10mmol/L), delivered by microdialysis in the forearm, with or without anesthesia. Then post-occlusive hyperemia and thermal hyperemia are performed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Microdialysis of fluconazole, vehicle and N(G)-nitro-L-arginine-methyl ester (L-NMMA)
Description: At the first three visits, volunteers will receive fluconazole (650µmol/L and 6.5mmol/L) and vehicle (NaCl 0.9%), and at the fourth, these plus L-NMMA (10mmol/L), delivered by microdialysis in the forearm, with or without anesthesia. Then post-occlusive hyperemia and thermal hyperemia are performed.
Study: NCT01046825

Intervention type: DRUG
Group type: OTHER
Intervention: COPAD
Description: Vincristine Prednis(ol)one, Cyclophosphamide, Doxorubicin, G-CSF~In the event the patient cannot receive G-CSF, Pegfilgrastim can be substituted.

Intervention type: DRUG
Group type: OTHER
Intervention: COP, COPD M3, CYM
Description: GROUP B Treatment Details Intravenous fluids should be given at a rate of 3000 mL/m2/day. Use of rasburicase may preclude the need for HCO3 Pre-Phase: Cyclophosphamide, Vincristine, Prednis(ol)one, IT medications Induction (2 cycles): Vincristine, Prednis(ol)one, Methotrexate, Leucovorin, Cyclophosphamide, Doxorubicin, IT medications, G-CSF, Rituximab Consolidation (2 cycles): Methotrexate, Leucovorin, Cytarabine, IT medications, G-CSF, Rituximab~In the event the patient cannot receive G-CSF, Pegfilgrastim can be substituted.

Intervention type: DRUG
Group type: OTHER
Intervention: COP, COPADM8, CYVE
Description: Treatment: Intravenous fluids should be given at a rate of 3000 mL/m2/day. Use of rasburicase may preclude the need for HCO3.~COP Pre-Phase: Cyclophosphamide, Vincristine, Prednis(ol)one, IT medications, Leucovorin.~COPADM8 Induction (2 cycles): Vincristine, Prednis(ol)one, Methotrexate, Leucovorin, Cyclophosphamide, Doxorubicin, Rituximab, IT medications, G-CSF CYVE Consolidation (2 cycles): Cytarabine, High-Dose Ara-C, Etoposide, Rituximab, G-CSF.~Maintenance No.1: Vincristine, Prednis(ol)one, Cyclophosphamide, Methotrexate, Leucovorin, Doxorubicin, IT medications, G-CSF.~Maintenance No.2: Cytarabine, Etoposide, G-CSF, IT Medications. Maintenance No.3: Vincristine, Prednis(ol)one, Cyclophosphamide, Doxorubicin, G-CSF, IT Medications.~Maintenance No. 4: Cytarabine, Etoposide, G-CSF, IT Medications.~In the event the patient cannot receive G-CSF, Pegfilgrastim can be substituted.
Study: NCT04458987

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expert patient in addictology
Description: EP's Intervention, with patients hospitalized for addiction withdrawal. These are weekly individual interviews, in room, proposed by the EPs to inpatients.~The content of the intervention will be defined trough the results of step one of the study.
Study: NCT03298633

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ICSI
Description: All patients will receive controlled ovarian hyperstimulation (COH) treatment, which is performed by standard routines at each study center. The COH treatment includes either gonadotrophin-releasing hormone agonist (GnRH-a) protocol or gonadotrophin-releasing hormone antagonist (GnRH-ant) protocol.Oocyte retrieval is scheduled for 36 (±2) after hCG injection.The retrieved cumulus oocyte complexes (COC) will be allocated to undergo routine ICSI procedure according to the result of randomization in each study site.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional IVF
Description: All patients will receive controlled ovarian hyperstimulation (COH) treatment, which is performed by standard routines at each study center. The COH treatment includes either gonadotrophin-releasing hormone agonist (GnRH-a) protocol or gonadotrophin-releasing hormone antagonist (GnRH-ant) protocol.Oocyte retrieval is scheduled for 36 (±2) after hCG injection.The retrieved cumulus oocyte complexes (COC) will be allocated to undergo conventional IVF procedure according to the result of randomization in each study site.
Study: NCT00676897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin 40mg PO or NGT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Corn Starch
Study: NCT03106298

Intervention type: DRUG
Intervention: Iron Sucrose
Description: All participants will be given intravenous iron sucrose (200 mg) weekly for 5 weeks. Iron sucrose is infused over 60 minutes.
Study: NCT01774019

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WallFlex™ Biliary RX Fully Covered/Uncovered Stent System
Study: NCT02883179

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine injection
Description: anhydrous solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine-prilocaine cream
Description: topical cream
Study: NCT00694733

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: Normal saline injection IM monthly for 4 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depo Lupron/Aromatase inhibitor
Description: Depo Lupron injection 7.5mg IM monthly for 8 months, with addition of testosterone gel and aromatase inhibitor months 4-8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depo Lupron/placebo
Description: Depo Lupron injection 7.5mg IM monthly for 8 months, with addition of testosterone gel and placebo months 4-8.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo Cream 1ml applied twice daily for four months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estrogen cream
Description: Estrogen cream 1 ml twice daily, dose titrated to maintain estradiol level between 60 and 280 pg/ml.
Study: NCT02742792

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Twenty-four strength training sessions consisted in exercises of extension and flexion knees, lat pull-down, elbow extension and flexion, sitting bench press and hip abduction.

Intervention type: OTHER
Group type: OTHER
Intervention: Advice on Lifestyle
Description: Patients receive advice on lifestyle. Patients will be asked to participate in the elderly group meetings the basic health unit linked to the hospital.
Study: NCT04301115

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: attachment
Description: unilateral attachment from rehine 83

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bridge
Description: tooth implant supported bridge

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONVENTIONAL
Description: conventional metalic partial denture
Study: NCT00716066

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous or syngeneic stem cell transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo autologous or syngeneic stem cell transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Syngeneic Bone Marrow Transplantation
Description: Undergo syngeneic bone marrow transplantation
Study: NCT04883021

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual Target Theta Burst Stimulation
Description: TMS treatment will be provided daily for 5 days, then daily for 5 days in week 2, and three times per week (Monday, Wednesday, Friday) in weeks 3 and 4.~Treatment targeting will occur at the Beam F3 and FP1 scalp regions as defined by the 10-20 EEG system and previous publications. A Magventure MagPro X100 figure-8 coil with theta burst capabilities will be used to deliver the stimulus, including intermittent theta burst stimulation to the DLPFC (2 seconds of 50-Hz triplets delivered at 5 Hz, 8 seconds intertrain interval, 600 total pulses) and continuous theta burst to the MPFC (continuous 50-Hz stimulation triplets, 600 pulses). Stimulation will be delivered at 110% of the resting motor threshold.
Study: NCT01510002

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total thyroidectomy
Description: Extracapsular total thyroidectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total thyroidectomy + prophylactic central neck dissection
Description: Extracapsular total thyroidectomy plus prophylactic central neck dissection
Study: NCT02073253

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation
Description: In the experimental phase with NIV ventilatory support with bilevel positive pressure was used for 30 minutes with the subject comfortably seated. The NIV (Vivo 40 Bi-Level, General Electric Company) was fitted to the face of volunteer through a face mask, was initially adopted an inspiratory pressure (IPAP) of 15 cm H2O and an expiratory pressure (PEEP) of 5 cmH2O, resulting in a variation in pressure of 10 cm H2O, where the IPAP would be increased, subject to the comfort of the patient until the patient reached a tidal volume of 6-8 ml / kg, not exceeding the maximum of 20 cmH2O for IPAP.
Study: NCT03500666

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot
Description: Robot lateral neck lymph node dissection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total endoscopic
Description: Total endoscopic lateral cervical lymph node dissection
Study: NCT00643435

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-efficacy enhancing interviewing techniques training
Description: Teaching by standardized patient instructors regarding use of self-efficacy enhancing interviewing techniques to be applied in patient encounters

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention
Description: These residents receive training provided by a standardized patient instructor, regarding the common co-occurrence of chronic medical and mental health problems, without any interviewing technique discussion or training.
Study: NCT01709955

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucomannan
Description: 750 MG of Glucomannan in capsule form

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 750 mg of Cellulose powder in a capsule form
Study: NCT02678364

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control eggs
Description: Control eggs containing no additional vitamin D beyond norm

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 eggs
Description: Vitamin D3-biofortified eggs

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 25-Hydroxyvitamin D3 eggs
Description: 25-Hydroxyvitamin D3-biofortified eggs
Study: NCT00397020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: divalproex ER
Description: Dose: 30mg per kg, rounded to nearest 500mg, dosed PO QHS. Adjustments made through trial to obtain serum valproic acid levels of 85-125 mcg/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: quetiapine
Description: Dose: 200mg PO QHS, titrated up to therapeutic dose of 600-800mg.
Study: NCT02406495

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: filcon IV 1
Description: contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ocufilcon D
Description: contact lens
Study: NCT01136447

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound
Description: Block catheter will be introduced using ultraosound

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Block catheter will be introduced using ultraosound
Study: NCT01290198

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Microdialysis of fluconazole, vehicle and N(G)-nitro-L-arginine-methyl ester (L-NMMA)
Description: At the first three visits, volunteers will receive fluconazole (650µmol/L and 6.5mmol/L) and vehicle (NaCl 0.9%), and at the fourth, these plus L-NMMA (10mmol/L), delivered by microdialysis in the forearm, with or without anesthesia. Then post-occlusive hyperemia and thermal hyperemia are performed.
Study: NCT02163798

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-week instructor-led Tai Chi training program
Description: A 12-week (45 min per day, 5 days per week) instructor-led Tai Chi training program was conducted in the Tai Chi group. Of the 5 days of exercise, 3 days were led by qualified instructors, and 2 other days for self-practice. Each session consisted of a 10-min standard warm-up, 30-min of Tai Chi exercise, and 5-min cool down stretching. The modified 32 Yang-style Tai Chi Chuan was used, because it could be learned within a relatively short time, and has been widely promoted in HK community. An exercise log was used to record the actual implementation of the training (instructor-led \& self-practice).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-week instructor-led brisk walking training program
Description: A 12-week (45 min per day, 5 days per week) instructor-led brisk walking training program was conducted in the walking group. Of the 5 days of exercise, 3 days were led by qualified instructors, and 2 other days for self-practice. Each session consisted of a 10-min standard warm-up, 30-min of walking exercise, and 5-min cool down stretching. An exercise log was used to record the actual implementation of the training (instructor-led \& self-practice).
Study: NCT04421313

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Fiber Supplementation
Description: 12 g of inulin or of maltodextrin in powder, to dilute in water once daily, during 1 month. Given in pre-weighted pots (one pot per day, similar color and aspect)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dietary Fiber Supplementation
Description: 12 g of inulin or of maltodextrin in powder, to dilute in water once daily, during 1 month. Given in pre-weighted pots (one pot per day, similar color and aspect)
Study: NCT01792596

Intervention type: OTHER
Group type: OTHER
Intervention: Pasta with protein
Description: Pasta with Protein

Intervention type: OTHER
Group type: OTHER
Intervention: Pasta with Fiber
Description: Pasta with Fiber

Intervention type: OTHER
Group type: OTHER
Intervention: Pasta
Description: Pasta
Study: NCT02005393

Intervention type: DEVICE
Group type: OTHER
Intervention: FICE Image Acquisition followed by NBI Image Acquisition
Description: Images Captured with FICE Device, followed by same locations imaged with NBI Image Acquisition System
Study: NCT00822666

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: comparison of two loading strategies of clopidogrel (300mg vs 900mg) in the two genetic profiles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: comparison of two loading strategies of clopidogrel (300mg vs 900mg) in the two genetic profiles
Study: NCT01168245

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-NICE-System
Description: sham TMS and sham cognitive training

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NICE-System
Description: TMS combined with cognitive training
Study: NCT03060213

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fun For Wellness (FFW)
Description: FFW consists of videos, games, and content teaching 14 skills to support seven drivers of change that promote well-being in I COPPE domains. The drivers form the acronym BET I CAN, which stands for: Behaviors, Emotions, Thoughts, Interactions, Context, Awareness, and Next Steps. B teaches basics of habit formation, including antecedents, behaviors, and consequences and techniques like goal setting, behavior tracking and rewards. E teaches how to build positive emotions and cope with negative ones. T teaches lessons from cognitive behavioral therapy. I builds communication skills such as empathy, listening and assertiveness. C teaches how to create healthier environmental contexts. A aims to increase insight. N emphasizes the need to make plans and anticipate barriers.
Study: NCT03011905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 4 ml DexaGalen 4 mg/ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl (Control)
Description: 4 ml NaCl 9 mg/ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paracetamol
Description: Premedication and as needed after operation